OBJECTIVES: Canagliflozin (CANA), an agent that inhibits sodium glucose co-transporter 2, has been shown to improve glycemic control in patients with T2DM in clinical trials. The current study described the early clinical characteristics and glycemic control of T2DM patients receiving different doses of CANA following approval of CANA in a real-world setting. METHODS: Adults with ≥1 diagnosis for T2DM and ≥6 months of clinical activity before first CANA prescription (index) were identified in the Cegedim Strategic Data US electronic medical records database, in which 60% of contributors are primary care providers. Patients were stratified by their first CANA daily dose (100mg [CANA100] or 300mg [CANA300]) observed in the database. Patients' clinical characteristics were assessed descriptively and HbA1c levels at baseline and 6 months after the index date were compared using paired sample t-test to evaluate glycemic control associated with CANA. RESULTS: A total of 9,805 CANA users were identified, among which 6,571 (67%) were in the CANA100 group (mean age: 59; 48% female; 75% white; mean Charlson Comorbidity Index [CCI]: 1.8; mean Diabetes Complications Severity Index [DCSI]: 0.9) and 3,234 (33%) were in the CANA300 group (mean age: 57; 44% female; 75% white; mean CCI: 1.6; mean DCSI: 0.8). Before the index date, 98% and 97% of patients were prescribed ≥1 antihyperglycemic agent, with a mean number of 5.6 and 5.5 antihyperglycemic agents per patient in the CANA100 and CANA300 groups, respectively. In the 6 months following CANA initiation, mean HbA1c values decreased from 8.4% to 7.9% (p<0.0001) among CANA100 patients and from 8.5% to 7.8% (p<0.0001) among CANA300 patients.  CONCLUSIONS: Patients treated with CANA in the real-world setting often received multiple prior diabetes treatments and had uncontrolled HbA1c levels. Patients taking CANA significantly improved their HbA1c values, with numerically greater improvement in those with CANA 300mg.